CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ: CERS) announced today the appointments of
Kenneth Trader as vice president, sales, North America, and Scott Buker
as senior director, North American market development. Both will join
the company in January 2014. Mr. Trader will be responsible for sales
operations in North America, including planning for anticipated product
launches as well as establishing and building the sales team responsible
for product adoption. Mr. Buker will be responsible for key launch
activities and for management of national accounts in North America.
Mr. Trader comes to Cerus with twenty-five years of leadership
experience in sales and marketing management, having served most
recently as vice president, sales and payer relations at US Bioservices,
a division of AmerisourceBergen Specialty Group. Prior to this role, Mr.
Trader served as vice president, corporate business development at
AmerisourceBergen Specialty Group. He has also previously held the roles
of vice president of sales and marketing, hemophilia health services
with Accredo Health Group, and director of national sales with Baxter
BioScience, a division of Baxter Healthcare Corporation. Throughout his
career, Mr. Trader has consistently demonstrated success in numerous
biologic product launches and in building out commercial organizations.
Mr. Trader has served on the National Hemophilia Foundation's board of
directors since 2010, and currently holds the position of vice chair.
“We are delighted to welcome Ken to the Cerus team at such an exciting
time in the company’s history,” said William ‘Obi’ Greenman, Cerus’
chief executive officer and president. “As we continue working to
advance the INTERCEPT Blood System in both the U.S. and Canada, Ken will
immediately play a significant leadership role in our ongoing launch
preparations for North America, given his depth of industry knowledge
and experience.”
Mr. Buker joins Cerus with over thirty years of sales and marketing
experience in the blood testing and processing industry. He most
recently served as executive director, strategic accounts, for
Biomedical Services at the American Red Cross. Prior to this role, Mr.
Buker served as senior director, corporate accounts, and director,
national accounts, also at the Red Cross. Before joining the American
Red Cross, he held leadership roles in sales and marketing at Whatman
plc, Johnson & Johnson, E.I. DuPont de Nemours, and Abbott Laboratories.
“Scott brings a wealth of experience to our North American sales
leadership team,” said Mr. Greenman. “His extensive understanding of the
U.S. blood banking industry and his past successes in establishing and
managing national hospital accounts will be key to our launch planning
and execution efforts.”
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood safety. In in vitro studies, the company’s INTERCEPT
Blood System has been demonstrated to inactivate a broad range of
viruses, bacteria and parasites that may be present in donated blood,
including established threats such as hepatitis B and C, HIV, West Nile
virus and bacteria, as well as emerging pathogens such as influenza,
malaria and dengue. Cerus currently markets and sells the INTERCEPT
Blood System for both platelets and plasma in Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. In the United States, Cerus is seeking
regulatory approval of the INTERCEPT Blood System for plasma and
platelets. The INTERCEPT red blood cell system is in clinical
development. See http://www.cerus.com
for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
This press release contains forward-looking statements. Any statements
contained in this press release that are not statements of historical
fact may be deemed to be forward-looking statements, including, without
limitation, statements relating to the potential regulatory approval and
commercial launch of the INTERCEPT Blood System in the United States and
other North American countries, including the timing thereof, and
customer adoption of the INTERCEPT Blood System in the United States and
other North American countries. These forward-looking statements are
based upon Cerus’ current expectations. Actual results could differ
materially from these forward-looking statements as a result of certain
factors, including, without limitation, the risk that Cerus may
encounter unanticipated difficulties complying with the prescribed
submission timing or other modular Premarket Approval application
requirements of FDA, or complying with other regulatory requirements for
product approval in the U.S. or other North American countries and the
risk that customers may not adopt the INTERCEPT Blood System in the U.S.
or other North American countries, as well as other risks detailed in
Cerus' filings with the Securities and Exchange Commission (SEC),
including in Cerus' quarterly report on Form 10-Q for the quarter
ended September 30, 2013, filed with the SEC on November 1, 2013. You
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press
release. Cerus does not undertake any obligation to update any
forward-looking statements as a result of new information, future
events, changed assumptions or otherwise.
Source: Cerus Corporation